Diabetes
Pharmacotherapies
Explore facts and recommendations for pharmacological treatments for diabetes.
We didn't find any resources that match your selection.
Please adjust your filter(s) and try again.
SOUL Trial Design and Baseline Characteristics
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease
The FLOW Trial Poster
The poster gives details of FLOW trial design, baseline characteristics and endpoints
The STRIDE Trial
STRIDE trial rationale, design and baseline characteristics
RISE T2D QW Semaglutide
This poster is an overview of RWE data with semaglutide
ADA 2024 Standards of Care
In this video we talk about guidelines from the American diabetes association Standards of care 2024
ADA Standards of Medical Care in Diabetes – 2024
Algorithms and updates from the 2024 guidelines.
GLP-1 RA Mechanism of Action (IME Content)
Visual review of GLP-1 RA's mechanism of action.
Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database
Manuscript summarizing results from a retrospective cohort study evaluating healthcare resource utilization, costs, and glycated hemoglobin levels in adult patients with T2D after discontinuing liraglutide therapy.
GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice
Manuscript exploring T2D management with emphasis on cardiovascular risk and CVOTs performed to date. Additionally includes clinical experience with GLP-1RAs for managing hyperglycemia and their impact on cardiovascular risk.
ADA Standards of Medical Care in Diabetes 2024: Algorithm for intensifying to injectable therapies (Poster)
Treatment algorithm of the 2024 American Diabetes Association (ADA) Standards of Medical Care in Diabetes referencing Figure 9.4 on selecting injectable therapy for patients with Type 2 Diabetes.
ADA Standards of Medical Care in Diabetes 2024: Use of glucose-lowering medications in the management of T2D (Poster)
An infographic of the 2024 American Diabetes Association (ADA) Standards of Medical Care in Diabetes referencing Figure 9.3 on the use of glucose lowering medications in the management of Type 2 Diabetes.
The Unmet Needs for Insulin Requiring Patients (Poster)
Explains barriers to daily insulin therapy and the benefit of a once-weekly dosing approach.
Cardiovascular Risk Reduction and Primary Prevention Recommendations (Poster)
A review of the 2020 ACC Expert Consensus Pathway and 2021 AHA/ASA guidelines for the prevention of stroke. Also includes patient and clinician considerations for initiating drug therapy with demonstrated CV benefit.
GLP-1 RAs and Cardiovascular Outcomes Trials (Poster)
A summary of key CV outcomes of GLP-1RAs on MACE endpoints and CV risk factors. Also highlights the possible mechanism of CV benefits and considerations for drug initiation and monitoring
ADA/KDIGO Consensus Report - 2022 (Poster)
Treatment algorithm for selecting glucose-lowering medication for patients with type 2 diabetes and chronic kidney disease.
Semaglutide Injection Mechanism of Action
This video discusses the mechanism of action and mechanism of protraction of the semaglutide injection.
Oral Semaglutide Mechanism of Action
This video discusses the mechanism of action of oral semaglutide.
Oral Semaglutide Mechanism of Absorption
This video discusses the mechanism of absorption of oral semaglutide.
Pharmacokinetic, Pharmacodynamic (PK/PD) & Dosing Considerations for Oral Semaglutide
This video describes PK/PD considerations that can impact the dosing of oral semaglutide.
Drug Interactions With Oral Semaglutide
This video reviews potential drug-drug interactions with oral semaglutide.
Oral Semaglutide vs. Placebo in Drug-Naïve Adults (PIONEER 1 Study)
This video discusses the trial-design and outcomes of the PIONEER 1 study. PIONEER 1 was a 26-week, phase 3a, randomized, double-blind, parallel group, multinational trial in 703 adult patients with type 2 diabetes managed with diet and exercise alone.
Oral Semaglutide 14 mg vs. Empagliflozin 25 mg (PIONEER 2 Study)
This video discusses the trial-design and outcomes of the PIONEER 2 study. PIONEER 2 was a 52-week, phase 3a, randomized, open-label, multinational trial enrolling 822 adults with type 2 diabetes.
Oral Semaglutide vs. Sitagliptin 100 mg (PIONEER 3 Study)
This video discusses the trial-design and outcomes of the PIONEER 3 study. PIONEER 3 was a 78-week, phase 3a, randomized, double-blind, double-dummy, multinational trial enrolling 1864 adults with type 2 diabetes.
Oral Semaglutide 14 mg vs. Liraglutide 1.8 mg vs. Placebo (PIONEER 4 Study)
This video discusses the trial-design and outcomes of the PIONEER 4 study. PIONEER 4 was a 52-week, phase 3a, randomized, double-blind, double-dummy, active- and placebo-controlled, multinational trial in 711 adults with type 2 diabetes.
Oral Semaglutide 14 mg vs. Placebo in Adults with Moderate Renal Impairment (PIONEER 5 Study)
This video discusses the trial-design and outcomes of the PIONEER 5 study. PIONEER 5 was a 26-week, phase 3a, randomized, double-blind, multinational trial enrolling 324 adults with type 2 diabetes and moderate renal impairment.
Cardiovascular Safety of Oral Semaglutide vs. Placebo (PIONEER 6 Study)
This video discusses the trial-design and outcomes of the PIONEER 6 study. PIONEER 6 was a phase 3a, randomized, double-blind, multinational trial that enrolled 3183 adult patients (age ≥50 years) with type 2 diabetes. Eligible patients were at least 50 years of age with established cardiovascular (CV) disease or chronic kidney disease, or patients were at least 60 years of age with at least one CV risk factor.
Flexible Dosing of Oral Semaglutide vs. Sitagliptin 100 mg (PIONEER 7 Study)
This video discusses the trial-design and outcomes of the PIONEER 7 study. PIONEER 7 was a 52-week, phase 3a, randomized, open-label, multinational trial with a 52-week extension enrolling 504 adults with type 2 diabetes.
Oral Semaglutide vs. Placebo as Add-on to Insulin (PIONEER 8 Study)
This video discusses the trial-design and outcomes of the PIONEER 8 study. PIONEER 8 was a 52-week, phase 3a, randomized, double-blind, parallel-group, multinational trial enrolling 731 adults with type 2 diabetes.
Find more information
Find product information
Explore our portfolio of products for treating diabetes, including prescribing information, safety data sheets, and storage and stability information.
Continuing education
Explore accredited diabetes education opportunities supported by Novo Nordisk and provided by third-party organizations.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
